Thrombosis
Conference Coverage
Pregnancy in rheumatic disease quadruples risk of cardiovascular events
Pregnant patients with lupus and concomitant APS had an 18-fold higher risk for a cardiovascular event during and up to 6 weeks postpartum than...
Latest News
Review finds no CV or VTE risk signal with use of JAK inhibitors for skin indications
Of the 35 trials studied, most involved patients with atopic dermatitis.
Conference Coverage
Longer edoxaban may benefit cancer patients with distal DVT
“This is the first and only randomized trial to show the superiority of longer duration over shorter duration of anticoagulation therapy for...
Feature
Factor XI inhibitors: The promise of a truly safe anticoagulant?
The efficacy data in the phase 3 trials will be key to the success of these drugs. “That is a very important part of the puzzle that is still...
Latest News
Steady VKA therapy beats switch to NOAC in frail AFib patients: FRAIL-AF
The switch resulted in more bleeding without any reduction in thromboembolic complications or all-cause mortality.
Latest News
Medicare announces 10 drugs targeted for price cuts in 2026
People on Medicare may in 2026 see prices drop for 10 medicines, including pricey diabetes, cancer, blood clot, and arthritis treatments.
Guidelines
New update on left atrial appendage closure recommendations
A new consensus statement on transcatheter left atrial appendage closure tightens standards for patient selection as well as operator experience...
Feature
Dabigatran recalled over potential carcinogen
The nationwide recall is because of the detection of the nitrosamine impurity, N-nitroso-dabigatran.
Conference Coverage
FREEDOM COVID: Full-dose anticoagulation cut mortality but missed primary endpoint
In an in-hospital anticoagulation trial, the primary COVID endpoint was missed but a survival benefit is observed.
20th Anniversary
20 years of clinical research in cardiology
“It’s unbelievable how much we’ve accomplished in the last 20 years” in cardiology, said Dr. Steven E. Nissen.
From the Journals
Artificial sweetener in ‘keto foods’ tied to cardiovascular risk
Artificial sweeteners are “generally recognized as safe” by the FDA, so there is no requirement for long-term safety studies, and little is known...